Dynamics of the Cytokine Response to Mycobacterium ulcerans during Antibiotic Treatment for M-ulcerans Disease (Buruli Ulcer) in Humans

被引:23
作者
Sarfo, F. S. [2 ]
Phillips, R. O. [2 ,3 ]
Ampadu, E. [4 ]
Sarpong, F. [5 ]
Adentwe, E. [5 ]
Wansbrough-Jones, M. [1 ]
机构
[1] St Georges Univ London, Dept Infect Dis, London SW17 0RE, England
[2] Komfo Anokye Teaching Hosp, Kumasi, Ghana
[3] KNUST, Sch Med Sci, Kumasi, Ghana
[4] MOH, Natl Buruli Ulcer Control Programme, Accra, Ghana
[5] Tepa Govt Hosp, Tepa, Ghana
关键词
INTERFERON-GAMMA; PULMONARY TUBERCULOSIS; INFECTION; TOXIN; STREPTOMYCIN; LESIONS; MYCOLACTONE; COMBINATION; EFFICACY; GROWTH;
D O I
10.1128/CVI.00235-08
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We have studied the evolution of the gamma interferon (IFN-gamma) and interleukin 10 (IL-10) responses after Mycobacterium ulcerans sonicate stimulation of whole blood from patients with early M. ulcerans lesions during treatment with rifampin and streptomycin for 8 weeks. Among the 26 patients, secretion of IFN-gamma increased during treatment, with a significant increase at 4 weeks and a further increase after 8 weeks overall. The increase was more rapid in patients with large or ulcerative lesions, becoming significant by 4 weeks. For small lesions, there was only a minor increase, which did not reach significance. There was no significant change in the median IL-10 response during antibiotic therapy, and there was no inverse correlation between IFN-gamma and IL-10 responses. These results demonstrate that an IFN-gamma secretory response to M. ulcerans developed, independently of IL-10 secretion, in patients whose M. ulcerans disease healed during antibiotic therapy.
引用
收藏
页码:61 / 65
页数:5
相关论文
共 25 条
[1]  
Asiedu K, 2000, WHOCDSCPEGBUI20001
[2]   Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease)v [J].
Chauty, Annick ;
Ardant, Marie-Francoise ;
Adeye, Ambroise ;
Euverte, Helene ;
Guedenon, Augustin ;
Johnson, Christian ;
Aubry, Jacques ;
Nuermberger, Eric ;
Grosset, Jacques .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (11) :4029-4035
[3]   DISSEMINATED TUBERCULOSIS IN INTERFERON-GAMMA GENE-DISRUPTED MICE [J].
COOPER, AM ;
DALTON, DK ;
STEWART, TA ;
GRIFFIN, JP ;
RUSSELL, DG ;
ORME, IM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (06) :2243-2247
[4]   Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of buruli ulcer in humans [J].
Etuaful, S ;
Carbonnelle, B ;
Grosset, J ;
Lucas, S ;
Horsfield, C ;
Phillips, R ;
Evans, A ;
Ofori-Adjei, D ;
Klustse, E ;
Owusu-Boaten, J ;
Amedofu, GK ;
Awuah, P ;
Arnpadu, E ;
Amofah, G ;
Asiedu, K ;
Wansbrough-Jones, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (08) :3182-3186
[5]   An outreach education and treatment project in Ghana for the early stage of Mycobacterium ulcerans disease [J].
Evans, MRW ;
Phillips, R ;
Etuaful, SN ;
Amofah, G ;
Adomako, J ;
Adjei, O ;
Dennis-Antwi, J ;
Lucas, SB ;
Wansbrough-Jones, MH .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2003, 97 (02) :159-160
[6]  
FIORENTINO DF, 1991, J IMMUNOL, V146, P3444
[7]   AN ESSENTIAL ROLE FOR INTERFERON-GAMMA IN RESISTANCE TO MYCOBACTERIUM-TUBERCULOSIS INFECTION [J].
FLYNN, JL ;
CHAN, J ;
TRIEBOLD, KJ ;
DALTON, DK ;
STEWART, TA ;
BLOOM, BR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (06) :2249-2254
[8]   Partial purification and characterization of biological effects of a lipid toxin produced by Mycobacterium ulcerans [J].
George, KM ;
Barker, LP ;
Welty, DM ;
Small, PLC .
INFECTION AND IMMUNITY, 1998, 66 (02) :587-593
[9]   Mycolactone:: A polyketide toxin from Mycobacterium ulcerans required for virulence [J].
George, KM ;
Chatterjee, D ;
Gunawardana, G ;
Welty, D ;
Hayman, J ;
Lee, R ;
Small, PLC .
SCIENCE, 1999, 283 (5403) :854-857
[10]   A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells [J].
George, KM ;
Pascopella, L ;
Welty, DM ;
Small, PLC .
INFECTION AND IMMUNITY, 2000, 68 (02) :877-883